Everand Logo

Welcome to Everand!

  • NPR

    In The Battle Against COVID-19, A Risk Of 'Vaccine Nationalism'

    The race to defeat the coronavirus is generating competition among nations and multinational companies that's being described as "vaccine nationalism."
    by Greg Myre May 27, 2020 3 minutes
    President Trump and China's President Xi Jinping, shown here in 2019, have both faced criticism for their handling of the coronavirus. Both leaders are now pushing hard for a vaccine. The U.S. has already agreed to pay a drug company more than $1 billion to produce a vaccine that's yet to be approved. Xi says if China succeeds in developing a vaccine, it will be declared "a global public good."

    The race to defeat the coronavirus can be viewed in two very distinct ways. One is based on international cooperation, with a vaccine treated as a "global public good." The other is competitive, a battle between nations that's being described as "vaccine nationalism."

    Many are hoping for the former, but are seeing signs of the latter.

    The main competition, on this and many other global issues, appears to be between the U.S. and China. Both President Trump and China's President Xi Jinping have faced criticism for their handling of the coronavirus outbreak.

    You’re reading a preview, subscribe to read more.

    More from NPR

    NPR3 min read
    Bearing Witness, Celebrating Strength: How Poetry Has Changed Lives For NPR's Audience
    From sparking the imagination to helping with mental health, listen to poems read by NPR readers and see how poetry has affected their lives.
    NPR3 min readAmerican Government
    Who Is Hope Hicks, The Former Trump Adviser Testifying In New York Criminal Trial?
    Hope Hicks was a communications director for the Trump White House and prosecutors may question her on her knowledge of the deals made during his first presidential run.
    NPR3 min read
    Scientists Welcome New Rules On Marijuana, But Research Will Still Face Obstacles
    When marijuana becomes a Schedule III instead of a Schedule I substance under federal rules, researchers will face fewer barriers to studying it. But there will still be some roadblocks for science.

    Related Books & Audiobooks